Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Adult
Aged
Aged, 80 and over
Benzamides
Drug Resistance, Neoplasm
/ genetics
Female
Heterografts
/ drug effects
Humans
Middle Aged
Molecular Targeted Therapy
/ methods
Mutation
Nitriles
Phenylthiohydantoin
/ analogs & derivatives
Phosphoinositide-3 Kinase Inhibitors
/ therapeutic use
Protein Kinase Inhibitors
/ pharmacology
Receptors, Androgen
/ drug effects
Signal Transduction
/ genetics
TOR Serine-Threonine Kinases
/ antagonists & inhibitors
Triple Negative Breast Neoplasms
/ genetics
PI3K pathway inhibitor.
Triple-negative breast cancer
androgen receptor
genomic alteration
luminal androgen receptor (LAR)
targeted therapy
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
04
2019
accepted:
18
10
2019
entrez:
12
2
2020
pubmed:
12
2
2020
medline:
14
4
2021
Statut:
epublish
Résumé
Luminal androgen receptor (LAR) breast cancer accounts for 10% of all triple-negative breast cancers (TNBC). Anti-androgen therapy for this subtype is in development, but yields only partial clinical benefits. In this study, we aimed to characterize the genomic alterations of LAR TNBC, to analyze activation of the PI3K signaling pathway and to compare the response to PI3K pathway inhibitors with that to anti-androgen therapy in patient-derived xenografts (PDX) of LAR TNBC.
Identifiants
pubmed: 32042320
doi: 10.7150/thno.36182
pii: thnov10p1531
pmc: PMC6993232
doi:
Substances chimiques
Benzamides
0
Nitriles
0
Phosphoinositide-3 Kinase Inhibitors
0
Protein Kinase Inhibitors
0
Receptors, Androgen
0
Phenylthiohydantoin
2010-15-3
enzalutamide
93T0T9GKNU
MTOR protein, human
EC 2.7.1.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1531-1543Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Ann Oncol. 2017 Oct 1;28(10):2595-2605
pubmed: 28945830
Cell. 2016 Sep 22;167(1):260-274.e22
pubmed: 27641504
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Cancer Discov. 2014 Sep;4(9):998-1013
pubmed: 25185190
Histopathology. 2008 Jan;52(1):3-10
pubmed: 18171412
Breast Cancer Res. 2009;11(3):R31
pubmed: 19463150
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Oncotarget. 2016 Jul 19;7(29):46482-46491
pubmed: 27374089
Int J Cancer. 2019 Oct 1;145(7):1902-1912
pubmed: 30859564
Ann Oncol. 2018 Aug 1;29(8):1634-1657
pubmed: 30032243
Curr Protoc Hum Genet. 2008 Apr;Chapter 10:Unit 10.11
pubmed: 18428421
Cancer Inform. 2012;11:147-56
pubmed: 22872785
Mol Oncol. 2013 Jun;7(3):625-36
pubmed: 23478236
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
Nature. 2016 May 25;534(7605):55-62
pubmed: 27251275
Eur Urol. 2017 Apr;71(4):630-642
pubmed: 27591931
BMC Genomics. 2010 Apr 21;11:256
pubmed: 20406497
Ann Oncol. 2012 Sep;23(9):2399-408
pubmed: 22357447
J Clin Oncol. 2018 Apr 1;36(10):981-990
pubmed: 29470143
Eur J Cancer. 2017 Aug;81:228-236
pubmed: 28502694
Br J Cancer. 2015 Mar 17;112(6):1059-66
pubmed: 25742469
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
Ann Oncol. 2016 May;27(5):812-8
pubmed: 27052658
Cancer. 2007 Aug 15;110(4):876-84
pubmed: 17620276
Bioinformatics. 2010 Jan 15;26(2):242-9
pubmed: 19906825
Cancer Res. 2001 Feb 15;61(4):1652-8
pubmed: 11245479
Clin Cancer Res. 2013 Oct 1;19(19):5505-12
pubmed: 23965901
Clin Cancer Res. 2009 Apr 1;15(7):2472-8
pubmed: 19276248
Bioorg Med Chem Lett. 2013 Mar 1;23(5):1212-6
pubmed: 23375793
Cancer Cell. 2011 May 17;19(5):575-86
pubmed: 21575859
Mol Cancer Ther. 2015 Mar;14(3):769-78
pubmed: 25713333
Theranostics. 2017 Feb 23;7(4):974-986
pubmed: 28382169
JAMA. 2017 Jun 27;317(24):2532-2542
pubmed: 28655021
Oncoimmunology. 2015 Jun 24;5(1):e1061176
pubmed: 26942074
Breast Cancer Res. 2014 Aug 08;16(4):406
pubmed: 25103565
Breast Cancer Res. 2013 May 11;15(3):R37
pubmed: 23663520
Medicine (Baltimore). 2015 Dec;94(52):e2341
pubmed: 26717372
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Cancer Treat Rev. 2018 Jul;68:102-110
pubmed: 29940524
Sci Rep. 2014 Sep 01;4:6255
pubmed: 25176561
Prostate. 2013 Sep;73(12):1291-305
pubmed: 23765603
Pigment Cell Melanoma Res. 2017 May;30(3):317-327
pubmed: 28140525
Clin Chem. 1999 Aug;45(8 Pt 1):1148-56
pubmed: 10430778
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Clin Cancer Res. 2013 Oct 1;19(19):5533-40
pubmed: 23948975
Lancet Oncol. 2017 Oct;18(10):1360-1372
pubmed: 28800861